Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?

Open Access
Publisher Website
Google Scholar
Abstract
Sir, Takayasu arteritis (TA) is a chronic, idiopathic, inflammatory disease that primarily affects large vessels [1]. The management of this disorder is largely unresolved, since a large number of patients fail to reach stable remission on conventional treatment [2]. Thus, the need for more efficacious medical therapies is paramount in order to spare steroids and to prevent long-term toxicity and reduce disease-related morbidity and eventual mortality [3]. Recently, Hofmann et al. [4] have claimed the safety and efficacy of anti-tumour necrosis factor (TNF) therapy in an open label study in 15 patients with TA. Here we present two more cases of Takayasu arteritis treated with anti-TNFα infliximab, in which clinical remission was observed.

This publication has 9 references indexed in Scilit: